REGENXBIO Inc.
RGNX · Price history
Price at last available close
$7.24
−$0.21 (-2.82%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About REGENXBIO Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system.
How they make money
REGENXBIO is a clinical-stage biotechnology company that generates revenue primarily through license fees, milestone payments, and collaborative research and development arrangements. The company leverages its proprietary NAV Technology Platform, consisting of a portfolio of adeno-associated virus (AAV) vectors, to develop and commercialize gene therapies, often sharing development costs and future profits with strategic partners.
Products & services
The company develops investigational gene therapies using its NAV Technology Platform, focusing on retinal, neuromuscular, and neurodegenerative diseases, including candidates such as surabgene lomparvovec (ABBV-RGX-314), RGX-202, RGX-121, and RGX-111.
Brands & revenue mix
Proprietary gene delivery platform utilizing AAV vectors.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Strategic pharmaceutical and biotechnology partnersSource
Customer concentration
The company's revenue is highly concentrated due to its reliance on a limited number of strategic collaboration agreements, which account for a significant portion of total revenue for the fiscal year ended December 31, 2025.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of clinical trial materials and potential commercial supply; specific supplier names are not disclosed.Source
Business relationships & partnerships
- AbbVie — A strategic collaboration to develop and commercialize RGX-314 for the treatment of wet age-related macular degeneration and diabetic retinopathy, involving shared costs and profit-sharing in the U.S.Source
- Nippon Shinyaku — A collaboration to develop and commercialize RGX-121 and RGX-111 for the treatment of MPS II and MPS I.Source
Competitors
- Gene therapy and biotechnology companies — The company faces competition from various entities developing gene therapies and other treatments for retinal, neuromuscular, and neurodegenerative diseases.Source
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
13
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
17
Poor
Financial Strength
11
Business Quality / Moat
28
Management
0
Growth Quality
28
Risk / Durability
21
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
37
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
47/100
Building Historical Record
Model Score 47/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Elevated debt risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for RGNX
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can RGNX maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can RGNX fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Does RGNX's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What specifically needs to improve for RGNX to reach sustainable profitability?
- •What future growth or profitability would be needed to justify RGNX's current valuation?
Essential Investment Snapshot
Wall Street Score
13
Opportunity Score
37
Market Cap
$477.9M
P/E Ratio
-1.8
EPS
$-3.79
52-Week High
$16.19
52-Week Low
$5.46
Beta
0.93
Analyst Target
$19.50
Shares Outstanding
51.6M
Total Revenue
$174.5M
Total Debt
$69.0M
Dividend
No current dividend
Liquidation Value / Share
$1.39
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Weakening momentum
Elevated movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for RGNX
Detected from reported data — verify before acting.Elevated debt risk
Total debt is at least one year of revenue • Interest coverage is below 2x • Free cash flow is negative
Community Sentiment
0 active · 0 total callsNo personal call yet on RGNX.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary NAV Technology Platform.
- +Broad pipeline of investigational AAV therapeutics.
Potential downside factors
- −Debt risk (elevated): Total debt is at least one year of revenue.
- −Interest coverage is below 2x.
- −Free cash flow is negative.
- −Dependence on strategic collaborations and third-party manufacturers.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
14
Oct 1, 2026
Change
-0.4
points
Current Score
13
Oct 15, 2026
Category Changes
RGNX decreased 0.4 points because Asset declined by 4 points.
Negative Contributors
- − Asset declined by 4 points
Projected Score
Projected Score
15
Projected Change
+1.8 points
Preliminary comparable-period financial changes suggest improvement of approximately 1.8 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$7.24
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: +104.5%
Revenue changed sharply from 2024 to 2025. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $174.5M | $170.4M | $83.3M | $90.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $19.9M | $20.3M | $33.6M | $37.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $154.6M | $150.1M | $49.8M | $53.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $233.0M | $228.3M | $208.5M | $232.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $85.6M | $82.9M | $76.6M | $88.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $318.8M | $311.3M | $283.1M | $321.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$139.1M | -$133.3M | -$198.2M | -$239.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$164.1M | -$161.2M | -$233.3M | -$268.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $41.9M | $45.0M | $12.7M | $6.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$196.4M | -$193.9M | -$227.1M | -$263.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$152K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$196.4M | -$193.9M | -$227.1M | -$263.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-3.79 | $-3.76 | $-4.59 | $-6.02 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 52.82M | 51.57M | 49.51M | 43.73M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 53.02M | 51.57M | 49.51M | 43.73M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$108.0M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$0.43
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-11.3%
Cash Change
-54.1%
Margin Change
+352.8 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Debt reduced
What Weakened
- Cash position declined
Potential Score Impact
Positive indicators included revenue growth, debt levels, net income margin. Pressure indicators included EPS growth, cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 405.7%. EPS declined 131.2%. Cash declined 54.1%. Total debt declined 11.3%. Net income margin improved by 352.8 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
REGENXBIO Inc. (RGNX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
REGENXBIO to Participate in Upcoming Investor Conferences
Rumor Mill · RGNX
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial